Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma ranks among the most lethal of human malignancies. Here, we assess the cooperative interactions of two signature mutations in mice engineered to sustain pancreas-specific Cre-mediated activation of a mutant Kras allele ( Kras G12D ) and deletion of a conditional Ink4a/Arf tumor suppressor allele. The phenotypic impact of Kras G12D alone was limited primarily to the development of focal premalignant ductal lesions, termed pancreatic intraepithelial neoplasias (PanINs), whereas the sole inactivation of Ink4a/Arf failed to produce any neoplastic lesions in the pancreas. In combination, Kras G12D expression and Ink4a/Arf deficiency resulted in an earlier appearance of PanIN lesions and these neoplasms progressed rapidly to highly invasive and metastatic cancers, resulting in death in all cases by 11 weeks. The evolution of these tumors bears striking resemblance to the human disease, possessing a proliferative stromal component and ductal lesions with a propensity to advance to a poorly differentiated state. These findings in the mouse provide experimental support for the widely accepted model of human pancreatic adenocarcinoma in which activated KRAS serves to initiate PanIN lesions, and the INK4A/ARF tumor suppressors function to constrain the malignant conversion of these PanIN lesions into lethal ductal adenocarcinoma. This faithful mouse model may permit the systematic analysis of genetic lesions implicated in the human disease and serve as a platform for the identification of early disease markers and for the efficient testing of novel therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These KRAS mutations are also found in the early stages of pancreatic ductal adenocarcinoma, preceding the appearance of senescence markers such as p53, CDKN2A and SMAD4196.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [196]
Experimental — accuracy not yet measuredIn the citing paper
“In a mouse model, CDKN2A loss accelerated KRASG12D-driven tumor growth54.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [54]
In the citing paper
“GEMMs with compound mutations that combine Kras mutation with the inactivation of tumor suppressor genes Cdkn2a and Tp53, or with the inactivation of the TGFβ-SMAD4 signaling pathway in the pancreas develop invasive and metastatic PDAC (74–76), thus validating the role of these tumor suppressor pathways in PDAC progression (4).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [74]
In the citing paper
“combined expression of oncogenic Kras coupled with the deletion or loss of function of Trp53, Cdkn2a, or Smad4 in the pancreas of mice readily leads to invasive PDAC29–32.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundAnalysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Self-citationZhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundSelf-citationTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 1×
“Although ARF is a known activator of the p53 pathway (Kamijo et al. 1998; Pomerantz et al. 1998; Stott et al. 1998; Zhang et al. 1998) and its loss clearly attenuates the function of that critical tumor suppressor, more recent studies have demonstrated that ARF has p53-independent…”
BackgroundSelf-citationGu, G., Dubauskaite, J., & Melton, D. A. (2002) · Development · doi:10.1242/dev.129.10.2447 · Cited by 1,518
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
Warshaw, A. L., & Castillo, C. F.-D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202133260706 · Cited by 1,198
Stott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167
Research works printed but not linked: 17
- 2003, Cancer Res., 63, 2005
- 1976, Cancer Res., 36, 2690
- 1990, Mol. Cell. Biol., 10, 1779
- 1992, Am. J. Pathol., 140, 1237
- 2003, Cancer Res., 63, 2016
- 2001, Cancer Res., 61, 4923
- 1994, Am. J. Pathol., 145, 1547
- 10.1002/(SICI)1098-2264(200004)27:4<358::AID-GCC4>3.0.CO;2-O · doi:10.1002/(sici)1098-2264(200004)27:4<358::aid-gcc4>3.0.co;2-o
- 10.1002/(SICI)1097-0142(19990415)85:8<1703::AID-CNCR9>3.0.CO;2-R · DOI
- 2001, Cancer J., 7, 242
- 1997, Cancer Res., 57, 2140
- 1997, Cancer Res., 57, 1731
- 1998, Biochim. Biophys. Acta, 1378, F115
- 1998, Cancer Res., 58, 4740
- 2000, Cancer Res., 60, 2002
- 1986, Jpn. J. Cancer Res., 77, 370
- 1994, Am. J. Pathol., 145, 671
Cited by
Items 701–800 of 999
Fan, K., Zhang, S., Ni, X., Shen, S., Wang, J., Sun, W., Suo, T., Liu, H., Ni, X., & Liu, H. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022173 · Cited by 13
Advancements in Preclinical Models of Pancreatic Cancer
Salu, P., & Reindl, K. M. (2024) · Pancreas · doi:10.1097/mpa.0000000000002277 · Cited by 15
Fukuda, J., Kosuge, S., Satoh, Y., Sekiya, S., Yamamura, R., Ooshio, T., Hirata, T., Sato, R., Hatanaka, K. C., Mitsuhashi, T., et al. (2024) · Cancer Science · doi:10.1111/cas.16100 · Cited by 14
Genetic Signature of Human Pancreatic Cancer and Personalized Targeting
Reshkin, S. J., Cardone, R. A., & Koltai, T. (2024) · Cells · doi:10.3390/cells13070602 · Cited by 14
“Tumors can release cells and parts of cells that can then be found in blood and other biological fluids.”
BackgroundGenetic alterations in precancerous pancreatic lesions and their clinical implications
Turrini, O., Cano, C. E., Legoffic, A., Delpéro, J., Dagorn, J., & Iovanna, J. (2009) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2009.08.007 · Cited by 13
Qian (2010) · Molecular Medicine Reports · doi:10.3892/mmr_00000301 · Cited by 13
“The rates of tumor inhibition were 52.7, 78.9, 78.2 and 97.1%, respectively, after treatment with 5-aza-dc on different days (3, 5, 7 and 9).”
InfluentialSewastianik, T., Jiang, M., Sukhdeo, K., Patel, S. S., Roberts, K. G., Kang, Y., Alduaij, A., Dennis, P. S., Lawney, B. P., Liu, R., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017012211 · Cited by 15
“Reverse transcription polymerase chain reaction/restriction fragment length polymorphism analyses were performed with RNA isolated from whole testes or CD19(1) splenocytes.(30) Survival analysis was performed by using the Kaplan-Meier method and compared by using the log-rank test.”
BackgroundMethodHeparanase Inhibition by Pixatimod (PG545): Basic Aspects and Future Perspectives
Hammond, E., & Dredge, K. S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-34521-1_22 · Cited by 13
Kandikattu, H. K., Manohar, M., Venkateshaiah, S. U., Yadavalli, C. S., & Mishra, A. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119640 · Cited by 14
Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts
Ruess, D. A., Görgülü, K., Wörmann, S. M., & Algül, H. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0453-y · Cited by 15
“Loss or promoter methylation of the CDKN2A gene promotes carcinogenesis and tumor progression [14, 84] and appears to be associated with invasion and metastasis in PDAC [13, 85].”
BackgroundTumor suppressor p16INK4a controls oncogenic K‐Ras function in human pancreatic cancer cells
Rabien, A., Sanchez‐Ruderisch, H., Schulz, P. M., Otto, N., Wimmel, A., Wiedenmann, B., & Detjen, K. M. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02140.x · Cited by 14
Warner, S. L., Muñoz, R. M., Bearss, D. J., Grippo, P. J., Han, H., & Hoff, D. D. V. (2008) · Pancreas · doi:10.1097/mpa.0b013e318176b9ae · Cited by 14
Preclinical Models of Regional Lymph Node Tumor Metastasis
Nathanson, S. D. (2007) · Cancer treatment and research · doi:10.1007/978-0-387-69219-7_10 · Cited by 15
Location, Location, Location: Precursors and Prognoses for Pancreatic Cancer
Hingorani, S. R. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.059 · Cited by 14
Notch Signaling: Where Pancreatic Cancer and Differentiation Meet?
Jean–Paul De La, O., & Murtaugh, L. C. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.03.022 · Cited by 15
Experimental models of pancreas cancer: what has been the impact for precision medicine?
Pantazopoulou, V., Kubota, C. S., Ogawa, S., Gulay, K. C. M., Lin, X., Song, H., Weitz, J., Tiriac, H., Lowy, A. M., & Engle, D. D. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191945 · Cited by 18
“The Pdx1-Cre LSL-Kras G12D Cdkn2a lox/lox model demonstrates accelerated tumorigenesis, emphasizing the cooperative effect of Cdkn2a loss and Kras activation (111).”
Identification and analysis of pancreatic intraepithelial neoplasia: opportunities and challenges
Pian, L.-L., Song, M.-H., Wang, T., Qi, L., Peng, T.-L., & Xie, K.-P. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1401829 · Cited by 24
OncogèneKraset cancer du pancréas: Trente ans plus tard
Bournet, B., Dufresne, M., Sèlves, J., Torrisani, J., Cordelier, P., & Buscail, L. (2013) · médecine/sciences · doi:10.1051/medsci/20132911015 · Cited by 19
Schütte, U., Bisht, S., Brossart, P., & Feldmann, G. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.534453 · Cited by 14
“Mice with additional knockout of the Ink4A/Arf locus, which results in abrogation of both murine p16 and p19 function, rapidly develop poorly differentiated carcinomas resulting in death before the age of 7 weeks [67].”
BackgroundMethodInducible Mouse Models for Cancer Drug Target Validation
Jeong, J. H. (2016) · Journal of Cancer Prevention · doi:10.15430/jcp.2016.21.4.243 · Cited by 13
“to express rtTA and GFP using the endogenous ROSA26 promoter and to generate tetO-KRAS.(41) In the presence of doxycycline, the mutant KRAS is expressed in pancreatic cells of these”
BackgroundMethodSingle and Multiple Gene Manipulations in Mouse Models of Human Cancer
Lehman, H. L., & Stairs, D. B. (2015) · Cancer Growth and Metastasis · doi:10.4137/cgm.s21217 · Cited by 13
Pancreatic Intraepithelial Neoplasia
Hruban, R. H., Brune, K. A., Fukushima, N., & Maitra, A. (2008) · Springer eBooks · doi:10.1007/978-0-387-69252-4_3 · Cited by 25
Genetically Engineered Knock-In and Conditional Knock-In Mouse Models of Cancer
Rappaport, A., & Johnson, L. (2014) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top069799 · Cited by 14
Pertussis: an update on primary prevention and outbreak control.
Scott, P. T., Clark, J. B., & Miser, W. F. (1997) · PubMed · Cited by 12
Sekiya, S., Fukuda, J., Yamamura, R., Ooshio, T., Satoh, Y., Kosuge, S., Sato, R., Hatanaka, K. C., Hatanaka, Y., Mitsuhashi, T., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3762 · Cited by 13
Kim, J., Jeon, Y. J., Lim, S., Ryu, J., Lee, J.-H., Chang, I. Y., & You, H. J. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04332-0 · Cited by 12
Nouveautés dans la biologie du cancer du pancréas
Buscail, L., Bournet, B., Dufresne, M., Torrisani, J., & Cordelier, P. (2015) · Bulletin du Cancer · doi:10.1016/s0007-4551(15)31218-2 · Cited by 14
Germinal Center B-Cells Resist Transformation by Kras Independently of Tumor Suppressor Arf
Mullins, C. D., Su, M. Y., Hucthagowder, V., Chu, L., Lu, L., Kulkarni, S., Novack, D. V., Vij, R., & Tomasson, M. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067941 · Cited by 12
“Arf (P14 in humans) is a potent tumor suppressor gene that cooperates with Ras activation in cellular transformation and carcinogenesis [21,22].”
BackgroundWeng, C., Lin, Y., & Cheng, K. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091369 · Cited by 12
Bintz, J., Abuelafia, A. M., Gerbe, F., Baudoin, E., Auphan‐Anezin, N., Sidot, E., Jay, P., & Iovanna, J. (2020) · Biology · doi:10.3390/biology9100341 · Cited by 11
“The mouse model of pancreatic adenocarcinoma used in this study resulted from crossbreeding of the following strains: Pdx1-cre [31], LSL-KrasG12D6 and Ink4a / Ar ffl/ fl [32,33].”
Delahoussaye, A. M., Jaoude, J. A., Green, M., Fujimoto, T. N., Molkentine, J. M., García, C. J. G., Gay, J. P., Feng, N., Marszalek, J. R., Fowlkes, N. W., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09255-3 · Cited by 11
“KPC mice were created by breeding KrasLSL− G12D/+ to Trp53fl/fl;Ptf1αCre/+, resulting in a KrasLSL− G12D/+;Trp53fl/+;Ptf1αCre (KPC) mice, which is a validated model of locally advanced pancreatic cancer [11].”
MethodMouse Models of Pancreatic Ductal Adenocarcinoma
Ponz‐Sarvisé, M., Tuveson, D. A., & Yu, K. H. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.04.010 · Cited by 11
Self-citationRAF/MEK Dependence of KRAS-Mutant Pancreatic Ductal Adenocarcinomas
Hanrahan, A. J., & Solit, D. B. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0308 · Cited by 12
“Furthermore, coincident loss of Ink4a/Arf or Trp53 function results in the development of invasive pancreatic adenocarcinomas that phenocopy the human disease (3, 4).”
Saito, Y., Xiao, Y. Q., Yao, J., Li, Y., Liu, W., Yuzhalin, A. E., Shyu, Y.-M., Li, H., Yuan, X., Li, P., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00720-w · Cited by 13
Self-citationHashimoto, A., & Hashimoto, S. (2024) · Cancers · doi:10.3390/cancers16234094 · Cited by 13
Neural function of Netrin-1 in precancerous lesions of the pancreas
Haidar, H., Bellon, A., Sleiman, K., Hocine, M., Rama, N., Gadot, N., Carpizo, D. R., Mehlen, P., & Mann, F. (2025) · Nature Communications · doi:10.1038/s41467-025-62299-4 · Cited by 17
Efthymiou, G., Compare, C., Lohmann, E., Kousteridou, P., Bertrand, P. M., Carr, H. S., Ben‐Sahra, I., Nemazanyy, I., Tubiana, S.-S., Hussain, Z., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu2276 · Cited by 11
Ink4a/Arf loss promotes tumor recurrence following Ras inhibition
VanBrocklin, M. W., Robinson, J. P., Lastwika, K. J., McKinney, A. J., Gach, H. M., & Holmen, S. L. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor184 · Cited by 10
A Historical Perspective on Clinical Advances in Pancreatic Diseases
Rustgi, A. K. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.03.010 · Cited by 10
Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma
Sobhani, N., Pittacolo, M., D’Angelo, A., & Marchegiani, G. (2025) · Cancers · doi:10.3390/cancers17040704 · Cited by 14
“The KRAS G21D mutation alone has been shown to result in PDAC formation and its protracted onset [38,39].”
Hashimoto, A., Handa, H., Hata, S., & Hashimoto, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1005566 · Cited by 11
Liou, G., Byrd, C. J., Störz, P., & Messex, J. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094726 · Cited by 10
“Furthermore, evidence from transgenic mouse studies demonstrated that oncogenic Kras G12D mutation is a necessity during PDAC initiation [23,42,43], progression and dissemination [44–46].”
BackgroundGenetic factors affecting patient responses to pancreatic cancer treatment
Fotopoulos, G., Syrigos, K., & Saif, M. W. (2016) · Annals of Gastroenterology · doi:10.20524/aog.2016.0056 · Cited by 10
“Mouse studies provide compelling evidence that oncogenic KRAS is required for the formation for the initiation and maintenance of invasive pancreatic cancers [72].”
BackgroundMechanisms Underlying Metastatic Pancreatic Cancer
Pitarresi, J. R., & Rustgi, A. K. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-22254-3_1 · Cited by 9
Generation and application of patient-derived xenograft models in pancreatic cancer research
Wang, C., & Shi, X. (2019) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000524 · Cited by 9
Genetic context of oncogenic drivers dictates vascular sarcoma development in aP2‐Cre mice
Hanna, J. A., Langdon, C. G., Garcia, M. R., Benton, A., Lanman, N. A., Finkelstein, D., Rehg, J. E., & Hatley, M. E. (2022) · The Journal of Pathology · doi:10.1002/path.5873 · Cited by 8
“…including: aP2-Cre (Tg(Fabp4-Cre)1Jmgr) [20], Dicer1 Flox (Dicer1 tm1Smr ) [21], LSL-Kras G12D (Kras tm4Tyj ) [22], Cdkn2a Flox (Cdkn2a tm4Rdp ) [23], Tsc1 Flox (Tsc1 tm1Djk ) [24], and R26-tdTomato (Gt(ROSA) 26sor tm14(CAG-tdTomato)/Hze ) [25], as detailed in supplementary material, Table S1.”
Modification of the L1-CAM carboxy-terminus in pancreatic adenocarcinoma cells
Chen, M. M., Lee, C.-Y., Leland, H. A., & Silletti, S. (2010) · Tumor Biology · doi:10.1007/s13277-010-0127-4 · Cited by 9
“Studies have identified key factors in PDAC etiology [3], which have been incorporated into a timeline that has been in part validated using transgenic mice [4, 5].”
BackgroundPancreatic Cancer: Novel Approaches to Diagnosis and Therapy
Rustgi, A. K. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.08.036 · Cited by 9
How much do we know about the metastatic process?
Rodríguez-Tirado, C., & Sosa, M. S. (2024) · Clinical & Experimental Metastasis · doi:10.1007/s10585-023-10248-0 · Cited by 10
“…model, a knock-in expression of KRAS (Kras G12D ) by Cre recombinase under the pancreatic promoter P48, is characterized by rapid development of PanIN lesions in the first weeks of life that resemble human PanINs I–III, with longer latency before PDAC is detected at around 30 weeks of age [55, 61].”
BackgroundThe Janus kinase 1 is critical for pancreatic cancer initiation and progression
Shrestha, H., Rädler, P. D., Dennaoui, R., Wicker, M. N., Rajbhandari, N., Sun, Y., Peck, A. R., Vistisen, K. S., Triplett, A. A., Beydoun, R., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114202 · Cited by 8
Gicquel, T., Marchianò, F., Reyes‐Castellanos, G., Audebert, S., Camoin, L., Habermann, B. H., Giannesini, B., & Carrier, A. (2024) · eLife · doi:10.7554/elife.93312.2 · Cited by 25
Lee, T., Kim, K., Lee, J., Park, S. H., Park, Y. S., Lim, H. Y., Kang, W. K., Park, J. O., & Kim, S. T. (2018) · Journal of Cancer · doi:10.7150/jca.26068 · Cited by 9
“[2-5] KRAS mutation has been known as crucial marker for PDC growth and maintenance and targeting the KRAS is inevitable component for realizing precision medicine to PDA.”
BackgroundID1 marks the tumorigenesis of pancreatic ductal adenocarcinoma in mouse and human
Tang, Y., Zhang, S., Li, J., Wu, C., & Fan, Q. (2022) · Scientific Reports · doi:10.1038/s41598-022-17827-3 · Cited by 7
Liot, S., Kholti, N. E., Balas, J., Genestier, L., Verrier, B., Valcourt, U., & Lambert, E. (2021) · Scientific Reports · doi:10.1038/s41598-021-94566-x · Cited by 8
A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma
Yamaguchi, T., Ikehara, S. K., Nakanishi, H., & Ikehara, Y. (2014) · The Journal of Pathology · doi:10.1002/path.4402 · Cited by 7
“Cdkn2a [7] or Trp53 [8] or both [9], Smad4 [10], Rb1 [11] and Pten [12] accelerated the progression of the pathway.”
BackgroundBaiting for Cancer: Using the Zebrafish as a Model in Liver and Pancreatic Cancer
Hwang, K. L., & Goessling, W. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-30654-4_17 · Cited by 14
Chemoprevention of Pancreatic Cancer: Ready for the Clinic?
Logsdon, C. D., & Abbruzzese, J. L. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0216 · Cited by 9
Development of the pancreas and pancreatic cancer.
Lewis, B. (2006) · Endocrinology and metabolism clinics of North America (Print) · doi:10.1016/j.ecl.2006.02.003 · Cited by 10
Ruff, S. M., & Pawlik, T. M. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2903101 · Cited by 9
Microdissection and Culture of Murine Pancreatic Ductal Epithelial Cells
Pylayeva‐Gupta, Y., Lee, K. E., & Bar‐Sagi, D. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-287-2_14 · Cited by 7
Malnutrition in Pancreatic Ductal Adenocarcinoma (PDA)
Zolghadri, Y., Choudhuri, S. P., Ocal, O., Layeghi‐Ghalehsoukhteh, S., Berhe, F., Hale, M. A., & Wilkie, T. M. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.11.014 · Cited by 10
Collignon, A., Silvy, F., Robert, S., Trad, M., Germain, S., Nigri, J., André, F., Rigot, V., Tomasini, R., Bonnotte, B., et al. (2018) · PubMed · doi:10.1080/2162402x.2018.1504727 · Cited by 11
Senescence-associated genes and non-coding RNAs function in pancreatic cancer progression
Cheng, Q., Ouyang, X., Zhang, R., Zhu, L., & Song, X. (2020) · RNA Biology · doi:10.1080/15476286.2020.1719752 · Cited by 8
Velthaus, J.-L., Iglauer, P., Simon, R., Bokemeyer, C., Bannas, P., Beumer, N., Imbusch, C. D., Goekkurt, E., & Loges, S. (2021) · Oncology Research and Treatment · doi:10.1159/000517616 · Cited by 9
Sankarasubramanian, S., Pfohl, U., Regenbrecht, C. R. A., Reinhard, C., & Wedeken, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.760705 · Cited by 7
Jugniot, N., Bam, R., & Paulmurugan, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-02445-2 · Cited by 7
Sheth, G., Shah, S. R., Sengupta, P., Jarag, T., Chimanwala, S., Sairam, K. V. V. M., Jain, V., Talwar, R., Dhanave, A., Raviya, M., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00369 · Cited by 7
Ma, J., Gong, F., Kim, E., Du, J. X., Leung, C., Song, Q., Logsdon, C. D., Luo, Y., Li, X., & Lu, W. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216694 · Cited by 7
Putting GWAS to the functional test: NR5A2 and pancreatic cancer risk
Murtaugh, L. C. (2013) · Gut · doi:10.1136/gutjnl-2013-305030 · Cited by 8
Biology, pathophysiology, and epidemiology of pancreatic cancer
Dariya, B., Alam, A., & Nagaraju, G. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819457-7.00001-3 · Cited by 13
Barrambana, S., Zamorano-Domínguez, E., Liaki, V., & Guerra, C. E. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115652 · Cited by 10
Zhuo, M., Mao, J., & David, C. J. (2023) · STAR Protocols · doi:10.1016/j.xpro.2023.102108 · Cited by 7
Jang, J., Ko, K.-P., Zhang, J., Jun, S., & Park, J. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2509534122 · Cited by 5
Sex-dependent development of Kras-induced anal squamous cell carcinoma in mice
Walcheck, M. T., Matkowskyj, K. A., Turco, A. E., Blaine‐Sauer, S., Nukaya, M., Noel, J., Rønnekleiv, O. K., & Ronnekleiv‐Kelly, S. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259245 · Cited by 6
“However, these studies focused on concomitant genetic mutations (e.g., Trp53, Ink4a/Arf)[9,33] or the influence of environmental changes (e.g., high-fat diet)[34] in addition to the Pdx1-Cre driven KrasG12D-mutation, which facilitate the onset of PDAC and consequent death at an early age (roughly four months for LSL-K…”
BackgroundLi, X., He, J., & Xie, K. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00664-x · Cited by 7
“There are various animal models that show great similarities to the morphology of human PDM and help to better understand human PDA initiation and progression [17, 21, 37, 38].”
BackgroundTumorigenesis and axons regulation for the pancreatic cancer: A mathematical approach
Chauvet, S., Hubert, F., Mann, F., & Mezache, M. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2022.111301 · Cited by 7
“Chronological appearances : Based on the previous characterisation of the KIC model ( [22] and our personal observations), the first appearance of ADM is around time t1 = 17 days, of PanIN around time t2 = 21 days and PDAC around time t3 = 35 days.”
MethodIjichi, H. (2022) · Cancers · doi:10.3390/cancers14194880 · Cited by 6
EZH2 links pancreatitis to tissue regeneration and pancreatic cancer
Lasfargues, C., & Pyronnet, S. (2012) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2012.05.010 · Cited by 6
Gout, J., Pommier, R. M., Vincent, D. F., Ripoche, D., Goddard‐Léon, S., Colombe, A., Treilleux, I., Valcourt, U., Tomasini, R., Dufresne, M., et al. (2013) · Pancreatology · doi:10.1016/j.pan.2013.02.001 · Cited by 6
“Activation of oncogenic KRASG12D in pancreatic progenitor cells in Pdx1-Cre; LSL-KRASG12D mice, results in PanIN lesions that evolve spontaneously to aggressivePDACat lowfrequencyandnot until an advancedage [2,3].”
BackgroundSánchez, P., Espinosa, M., Maldonado, V., Barquera, R., Gabiño‐López, N. B., Torres, J., Cravioto-Villanueva, A., & Meléndez-Zajgla, J. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05592-3 · Cited by 6
“Previous reports have shown that PDAC present recurrent KRAS amplifications [42].”
ResultThe Molecular Pathology of Precursor Lesions of Pancreatic Cancer
Singhi, A. D., & Maitra, A. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_5 · Cited by 7
Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype?
Chandana, S. R., & Mahadevan, D. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001240 · Cited by 7
Effect of cigarette smoke exposure and mutant Kras overexpression on pancreatic cell proliferation
Glauert, H. P., Elliott, R. S., Han, S. G., Athey, M., Lee, E. Y., & Gairola, C. G. (2017) · Oncology Letters · doi:10.3892/ol.2017.5606 · Cited by 7
Vorläuferläsionen pankreatobiliärer Karzinome
Sipos, B., & Henopp, T. (2011) · Der Pathologe · doi:10.1007/s00292-011-1513-4 · Cited by 6
Pancreatic cancer cachexia: A systemic consequence of multi-organ interactions
Xiao, A., Feng, Y., Yin, B., Zhang, J., Cao, Z., Liu, X., Liang, Y., & Wu, W. (2025) · hLife · doi:10.1016/j.hlife.2025.05.002 · Cited by 6
Transgelin defines pro-tumorigenic cancer-associated fibroblasts in pancreatic cancer
Wang, X., Shinjo, K., Kumegawa, K., Maruyama, R., Mii, S., Shiraki, Y., Nishimura, T., Murofushi, Y., Suzuki, M., Kabasawa, T., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03299-5 · Cited by 12
McAndrews, K. M., Mahadevan, K. K., Li, B., Comptdaer, A. M., Sockwell, A. M., Morse, S. J., Kelly, P. J., Patel, S. I., Kirtley, M. L., Diaz, B. A. M., et al. (2026) · The EMBO Journal · doi:10.1038/s44318-026-00854-5 · Cited by 12
“…al, 2017) and genetically engineered mouse models (GEMMs) have revealed that oncogenic KRAS (KRAS * ) is critical for PDAC initiation and maintenance (Aguirre et al, 2003; Collins et al, 2012; Hingorani et al, 2003; Mahadevan et al, 2023a; Ying et al, 2012), suggesting that targeting KRAS * may…”
Akt Signaling Accelerates Tumor Recurrence Following Ras Inhibition in the Context of Ink4a/Arf Loss
Robinson, G. L., Robinson, J. P., Lastwika, K. J., Holmen, S. L., & VanBrocklin, M. W. (2013) · Genes & Cancer · doi:10.1177/1947601913513268 · Cited by 5
“In the absence of Cre, homozygous Ink4a/Arf mice and cells isolated from these mice express normal levels of p16 and p19.(13) Intracranial injection of TRE-KRas, Tet-off, Akt, and Cre containing retroviruses into newborn Nestin-TVA;Ink4a/Arf mice resulted in tumor formation in greater than 80% of injected mice (Fig.”
BackgroundApoptosis: Signaling Pathways in Pancreatic Cancer Pathogenesis
McConkey, D. J., & Choi, W. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_14 · Cited by 5
Blyth, K., Morton, J. P., & Sansom, O. J. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.02.009 · Cited by 7
“To address this, a number of other models of PDAC have been generated where Kras mutation is combined with other tumour suppressor mutations, for example LKB1, Pten, Ink4A and Smad4 [7 ,8 ,9,10].”
BackgroundYabushita, S., Fukamachi, K., Kikuchi, F., Ozaki, M., Miyata, K., Sukata, T., Deguchi, Y., Tanaka, H., Kakehashi, A., Kawamura, S., et al. (2013) · Pancreas · doi:10.1097/mpa.0b013e3182883624 · Cited by 5
Pathological Changes in Pancreatic Carcinogenesis: A Review
Yamakawa, K., Ye, J., Nakano‐Narusawa, Y., & Matsuda, Y. (2021) · Cancers · doi:10.3390/cancers13040686 · Cited by 6
“Engineering mice that express oncogenic Kras in the pancreas in combination with a conditional Ink4a/Arf of the p53-null allele [34,35] or a conditional knock-in mutant p53R172H [36] developed lethal metastatic PDACs with complete penetrance and shorter latency.”
BackgroundOncogenic KRAS, Mucin 4, and Activin A‐Mediated Fibroblast Activation Cooperate for PanIN Initiation
Hu, C., Huang, C., Hsu, M., Chien, H., Wu, P., Chen, Y., Jeng, Y., Tang, S., Chung, M., Shen, C., et al. (2023) · Advanced Science · doi:10.1002/advs.202301240 · Cited by 7
Ganaie, A. A., Parray, A., Hussain, T., Shabaneh, A., Jamroze, A., Ferrari, M. G., Wang, L., Liao, D. J., Koochekpour, S., Nanda, S., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.05.002 · Cited by 4
The physiological characteristics of the basal microvilli microvessels in pancreatic cancers
Ma, L., Han, X., Gu, J., Li, J., Lou, W., Jin, C., & Saiyin, H. (2020) · Cancer Medicine · doi:10.1002/cam4.3177 · Cited by 5
Detection of Tumor Suppressor Genes in Cancer Development by a Novel shRNA-Based Method
von Burstin, J., Diersch, S., Schneider, G., Reichert, M., Rustgi, A. K., & Schmid, R. M. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0709 · Cited by 5
“It is important to realize that pancreatic loss p16/p19 on its own does not result in PanIN or PDAC development in mice (23).”
BackgroundPrecursor Lesions of Pancreatic Cancer
Matthaei, H., & Maitra, A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6694-0_19 · Cited by 5
CA19-9 as a therapeutic target in pancreatitis
Kato, S., & Honda, K. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.161 · Cited by 5
“It has been reported that it takes several months for Kras/PDX1-cre mice to develop invasive cancers, and that additional mutations in tumor-suppressor genes such as TP53 (14) or CAKN2A (15) accelerates pancreatic tumorigenesis and increases aggressiveness.”
BackgroundEnglish, I. A., Worth, P. J., Hawthorne, K., Vergara, M., Pelz, K. R., Kiemen, A. L., Shah, V., Blise, K. E., Pelz, C., Tsuda, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.14.664767 · Cited by 7
Foth, M., Kim, W., O’Toole, K. T., Murphy, B., Justo-Garrido, M., Boggaram, S. S., Ghazi, P. C., Brennan, E., Wright, M. I., Shepherd, T., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-26-1313 · Cited by 6
Metadata
- Authors
- Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A.
- Affiliations
- Harvard University (US)
- Abramson Cancer Center (US)
- Brigham and Women's Hospital (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2003-01-01
- Volume
- 17
- Issue
- 24
- Pages
- 3112-3126
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- PMC
- PMC305262
- OpenAlex
- W2126663928
- Cited by
- 1,033
- References
- 84
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 38 · 2023: 34 · 2022: 40 · 2021: 67 · 2020: 46 · 2019: 45 · 2018: 46 · 2017: 55 · 2016: 49 · 2015: 63 · 2014: 69 · 2013: 67 · 2012: 53
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- Lustgarten Foundation
- Dana-Farber Cancer Institute
- Barr Foundation
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- pancreatic ductal adenocarcinoma, KRAS G12D, Ink4a/Arf, tumor suppressor inactivation, pancreatic intraepithelial neoplasia, premalignant pancreatic lesions, metastasis, mouse tumor model, tumor progression, stromal cell proliferation
- MeSH terms
- Animals, Fibroblasts, Humans, Mice, Transgenic, Pancreatic Neoplasms, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Viral Proteins, Tumor Suppressor Protein p53, Mice, Knockout, Integrases, Cyclin-Dependent Kinase Inhibitor p16, Carcinoma, Pancreatic Ductal, Tumor Suppressor Protein p14ARF, Vascular Endothelial Growth Factor A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.